Lopende studies in AZ Sint-Lucas

Anesthesie

Studieteam

• Dr. Freekje Viaene

Lopende studies

• UTTX: Uterustransplantatie vanuit de multi-orgaandonor: een prospectieve studie - donatieluik.

Endocrinologie

Studieteam

• Dr. Inge Van Boxelaer

Lopende studies

• CORDELIA: Continuous glucose monitoring for women with gestational diabetes: a randomized controlled trial.

Fertiliteit

Studieteam

• Dr. Nele Van Renterghem

Lopende studies

• HYFOIL: Live birth after additional tubal flushing with oil-based contrast versus no additional flushing: a randomised, multicentre, parallel group pragmatic trial in infertile women with at least one patent tube at Hysterosalpingo-foam sonography.

Gynaecologie

Studieteam

• Dr. Victoria Bracke
• Dr. Rawand Salihi

Lopende studies

• Elevate: Early dEtection of cerVical cAncer in hard-to-reach populations of women through portable and point-of-care HPV Testing.
• B.OSS B.OSS: Belgian Obstetric Surveillance System.
• VULVA: Gegevensverzameling van vrouwen die gediagnosticeerd zijn met vulvacarcinoom (VULVA).

Hart-en vaatziekten

De dienst hart- en vaatziekten neemt intensief deel aan internationale wetenschappelijke fase 2b en fase 3 studies waardoor patiënten de kans krijgen deel te nemen aan onderzoek met nieuwe, veelbelovende medicatie voor specifieke hart- en vaataandoeningen. Specifiek opgeleide studieverpleegkundigen zorgen voor de opvolging, samen met de arts.

Studieteam

• Dr. Hermans Kurt
• Dr. Vandekerckhove Hans
• Dr. Katarina van Beeumen

Lopende studies

• BE.REAL: A Belgian Registry to Evaluate the reAl life treatment with incLisiran on top of standard of care lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: the Belgian REAL (BE.REAL) registry.
• BI_1378-0020 A Phase III: double-blind, randomised, parallel-group superiority trial to evaluate efficacy & safety of the combined use of oral BI 690517 & empagliflozin compared with placebo & empagliflozin in participants with symptomatic heart failure & LVEF >40%.
• COL BE PCI: Colchicine in Belgium in patients with coronary artery disease after percutaneous coronary intervention.
• CRD-750-201: Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction.
• EHRA-PATHS WP5 EHRA-PATHS: Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, patient-centred systematic care pathways Clinical and health economic evaluation of new care pathways.
• Librexia-ACS A Phase 3: Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome.
• MILOS: Non-interventional study on the treatMent with bempedoIc acid and/or its fixed-dose combination with ezetimibe in routine clinical practice in patients with primary hyperchoLesterolemia Or mixed dySlipidemia.
• OCCL-ILR: Implantable loop recorder based diagnosis of SVT post PFO Closure with the Occlutech PFO device: a multicenter analysis.
• Ocean(a): A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a).
• PHYNAL: Prospective left main physiology registry.
• SCAD REGISTRY: A registry of Spontaneous Coronary Arterial Dissection.
• SOS-AMI: Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI).
• Victorian-2-Prevent: A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease.

Heelkunde

Studieteam

• Dr. Kjell Fierens
• Dr. Elodie Melsens

Lopende studies

• BEET-IT: Use of beetroot juice to protect against postoperative ileus following colorectal surgery
  
• M2R2: M2R2 Collaborative. Multicenter Ventral Mesh Rectopexy Registry

Huidziekten

De dienst huidziekten neemt actief deel aan klinische studies die de behandelingsmogelijkheden voor allerhande huidaandoeningen evalueren zoals psoriasis, eczeem en huidkanker. Zo blijft de dienst op de hoogte van de meest recente ontwikkelingen en garanderen ze de beste behandeling voor de patiënt.

Studieteam

• Dr. Chevolet Ines
• Dr. Dierckxsens Laurence
• Dr. Heughebaert Carol
• Dr. Kint Bernard
• Dr. Lissens Esther
• Dr. Pescod Stefanie

Lopende studies

• BENEBIO: Dosis reductie van de nieuwe generatie biologicals (IL7 en IL23 inhibitoren) bij psoriasis: een pragmatische, multicentrische gerandomiseerde, gecontroleerde, niet-inferioriteitsstudie. www.benebio.info
• BIOLOPTIM: Evaluatie van de voorspellende waarde van vroegtijdige serumconcentraties en anti-drug antilichamen van 6 biologics en het opstellen van een concentratie-responscurve voor deze producten bij psoriasis patiënten.
• Flex-up A Phase 3b/4: Randomized, Blinded, Treat-to- Target, Dose-Flexibility Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis.
• Hi-LIGHT: Hidradenitis suppurativa patients treated with bimekizumab: a real-life long-term prospective observation of health outcomes (Hi-LiGHT) study.
• INCB54707-301 A Phase 3: Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa.
• Serena: Long term observational, prospective study to collect in a real life setting data on the retention, effectiveness, safety, treatment pattern, quality of life, and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis.
• Stop-HS LTE Phase 3: Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa.

Kinderziekten

Studieteam

• Dr. Sarah De Schryver

Lopende studies

• DBPCFC - SPT - C: Dubbelblinde placebogecontroleerde voedingsallergietesten in de praktijk: uitwerking van een breed kader voor de uitvoering ervan - Proof of concept testvoedingen via huidpriktesten bij kinderen.
• EPI-ROTA-067 BOD BE DB: An observational study to assess the trends in confirmed rotavirus gastroenteritis (RV GE) hospitalisations and to assess the impact of the switch from current to Porcine circovirus (PCV)-free GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus vaccine, in children aged <2 years, in Belgium.

Laboratorium

Studieteam

• Dr. Jos Van Acker
• Dr.Anne-Marie Van den Abeele

Lopende studies

• HDV Epidemiology of Hepatitis Delta Virus in Belgium: a prospective cross-sectional cohort study.
• NAC: National Antibiogram Comittee.

Longziekten

Studieteam

• Dr. Filip Triest

Lopende studies

• Ozawade: refractaire hypersomnolentie bij OSAS onder CPAP therapie.
• Predictumab: Predictive factors and magnitude of response to Omalizumab and Mepolizumab in allergic and eosinophilic severe asthma, an open-label, controlled, randomized multinational pragmatic trial.

Maag-, darm- en leverziekten

De dienst maag-, darm- en leverziekten werkt actief mee aan klinische studies rond IBD. Inflammatoire darmziekten (=IBD), zoals de ziekte van Crohn en Colitis Ulcerosa, zijn tot op heden nog niet te genezen. Deze aandoeningen hebben een grote invloed op de kwaliteit van leven van de patiënt. Daarom is het van groot belang om door middel van wetenschappelijk onderzoek de verschillende bestaande behandelingen te optimaliseren, nieuwe behandelingsmogelijkheden te onderzoeken en de veiligheid van de behandelingen op lange termijn te bestuderen. Als patiënt word je tijdens deze studies heel nauw opgevolgd om elk effect van de behandeling te kunnen opsporen.

Naast de IBD-studies werkt deze dienst ook mee aan studies rond tumoren van het spijsverteringsstelsel en infecties (Clostridium difficile).

Studieteam

• Dr. Frederik De Clerck
• Prof. Dr. Peeters Harald
• Dr. Rogge Sofie
• Dr. Strubbe Beatrijs
• Dr. Van Ongeval Johan

Lopende studies

• ABTECT-MAINTENANCE: A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis.
• ABTECT-2: A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis.
• AMARETTO: Subcutaneous infliximab after a previous intravenous dose optimization.
• BALLAD: Ballad Blegium: a trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma.
• CARUC-ASA: Characterizing And Predicting the Remission status in patients with Ulcerative Colitis treated with 5-ASA and analyzing its impact on clinical relapse.
• Crossing: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING).
• Elevate UC OLE: An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis.
• GALOCEAN: A prospective, non-interventional, multi-country cohort study of the effectiveness and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis.
• HYRISS HYRISS: A multicenter, international, prospective, non-interventional, observational study, to assess treatment retention of an adalimumab biosimilar (Hyrimoz®) in IBD patients in real life setting.
• IMPACT - IBD: Assessing the effect of newer treatment molecules for IBD on extra- intestinal manifestations and concurrent immune mediated inflammatory diseases.
• LEGACY studie: Een langetermijn niet-interventionele registratiestudie ter beoordeling van de veiligheid en effectiviteit van Humira® (Adalimumab) bij patiënten met matige tot ernstige, actieve colitis ulcerosa (CU).
• Omicrohn: Active RandoMIsed Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN’s Disease: OMICROHN.
• ON-TRK: Prospective non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib.
• POMEROL: Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL trial.
• Rescue: Loss of RESponse to Ustekinumab treated by dose Escalation.
• Rescue-OLE: Een open-label uitbreiding en lange termijn werkzaamheids- en veiligheidsmonitoringstudie van patiënten met de ziekte van Crohn die eerder werden opgenomen in de studie met verlies van RESpons op Ustekinumab behandeld door dosis-Escalatie.
• Soprano CD: Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis.
• Vitabiotic: A 14-week pilot prospective clinical trial with BiOkuris product in patients with irritable bowel syndrome.

Neus-, keel- en oorziekten

Studieteam

• Dr. Stefan Delreu
• Dr. Philippe Leune

Lopende studies

• Nasumab II: Real life study assessing long term outcomes and predictive factors of response to biologicals in patients with severe Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) with or without comorbid asthma.
• Effect of outpatient vestibular revalidation in patients with unilateral vestibular hypofunction: retrospective analysis.

Neurochirurgie

Studieteam

• Dr. Kristel Vanchaze

Lopende studies

• FOOT DROP: a prospective, multi-center, randomized, parallel-group controlled trial to compare conservative versus surgical treatment of foot drop in peroneal nerve entrapment – Foot Drop.

Neurologie

Het neurologisch studiecentrum neemt deel aan klinische studies die nieuw ontwikkelde behandelingsmogelijkheden evalueren op effectiviteit en efficiëntie. Deze studies zijn actueel, vooral gericht op eerder zeldzame neuromusculaire aandoeningen zoals ALS, myasthenia gravis en myositis.

Studieteam

• Prof. dr. De Bleecker Jan
• Dr. Loret Griet
• Dr. Pieter Olivier

Lopende studies

• ABCURO: A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis.
• ABCURO OLE: An Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body Myositis.
• ADAPTsc+: A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis.
• ALKIVIA: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy.
• APL2-ALS-206: A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS).
• ARDA +: A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
• ARGX-113-2007: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy.
• ARGX-117-2002: A phase 2, randomized, double-bind, placebo-controlled, parallel-group, multicenter trial to evaluatie the safety and tolerability, efficacy, pharmacokinetics, and immunogenicity of 2 dose regimens of ARGX-117 in adults with multifocal motor neuropathy.
• ARGX-117-2003: A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy.
• ARGX-113-2011: A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy.
• CARDINALS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, Pk, and Biomarker Effects Of Ptc857 in Adult Subjects with Amyotrophic Lateral Sclerosis.
• DBS batterijen
• DBS RETRO: Deep Brain Stimulation (DBS) Retrospective Outcomes Study.
• Dystonia Registry: Registry of Deep Brain Stimulation with the VERCISE™ System for treatment of Dystonia: Vercise DBS Dystonia Registry.
• Essential Tremor Registry: Boston Scientific Registry of Deep Brain Stimulations for treatment of Essential Tremor (ET).
  
• MOM-M281-011: Een gerandomiseerd, dubbelblind, placebogecontroleerd fase 3-onderzoek in meerdere centra ter beoordeling van de werkzaamheid, veiligheid, farmacokinetiek en farmacodynamiek van nipocalimab toegediend aan volwassenen met gegeneraliseerde myasthenia gravis.
• Pompe Disease Registry
• R3918-MG-2018: Werkzaamheid en veiligheid van de combinatiebehandeling met pozelimab en cemdisiran bij patiënten met symptomatische gegeneraliseerde myasthenia gravis.
• Vercise registry Parkinson: Registry of Deep Brain Stimulation with the VERCISE™ System: Vercise DBS Registry.

Oncologisch studiecentrum

Het Oncologisch Studiecentrum neemt deel aan wetenschappelijk onderzoek rond kankerbehandeling. Ondanks de grote vooruitgang die de laatste decennia op het vlak van kankerbehandeling geboekt is, genezen patiënten niet altijd. Daarom is het noodzakelijk om door middel van wetenschappelijk onderzoek te blijven zoeken naar nieuwe behandelingsmethoden. Naast de bestaande medicatie zijn tal van geneesmiddelen ter bestrijding van kanker nog in ontwikkeling.

Studieteam

• Medisch oncologen:
  • Dr. Stefanie De Waele
  • Dr. Glen Meert
  • Dr. Daphne Serruys
  • Dr. Vincent Renard
• Longartsen
  • Dr. Elke Govaerts
  • Dr. André Verstraeten
• Radiotherapeuten
  • Dr. Wim Duthoy
  • Dr. Vanhoutte Ilse
  • Dr. Van de Voorde Lien
• Hematologen
  • Dr. Maxim Clauwaert
  • Dr. Eva Steel

Lopende studies

Gynaecologische oncologie

• AGO-OVAR / BGOG-ov34: Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial.
• Gloriosa: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
• KEYNOTE-A18: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer
• MIRASOL IMGN853-0416: A randomized, open-label, phase 3 study of mirvetuximab soravtansine versus investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
• IMGN853-0424: A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression.

• XPORT-EC-042: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-type, advanced or recurrent Endometrial Carcinoma.

Senologische oncologie

• C4391022: An Interventional, open-label, randomized, multicenter phase 3 study of PF-07220060 plus fulvestrant compared to investigator's choise of therapy in participants over 18 years of age with hormone receptor positive HER2-negative advanced/metastatic breast cancer whose disease progressed after prior CDK 4/6 inhibitor based therapy.
• Cambria-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamox).
• Serena-4: A randomized, multicentre, double-blind, phase III study of AZD9833 (an oral SERD) plus palbociclib versus anastrazole plus palbociclib for the treatment of patients with estrogen receptor-positive, HER2-negative advanced breast cancer who have not received any systemic treatment for advanced disease.
• TROPION-BREAST03: A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy.

Radiotherapie

• GROINSS: Groningen International Study on Sentinel Nodes in Vulvar Cancer-III, a Prospective Phase II Treatment Trial.
• DART: Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial.
• ProCaLung: The Project on Cancer of the Lung.
• 1811 - E2-RADiaTE - 1822 - Oligocare 1811: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe 1822: A pragmatic observational cohort study to evaluate radical radiotherapy for oligo-metastatic cancer patients.

Thoracale oncologie

• A2A-005: A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell lung cancer who have progressed on immunotherapy.
• CARMEN studie: Randomized, open label phase 3 study of SAR408701 versus Docetaxel in previously treated metastatic non-squamous non-small cell lung cancer patients with CEACAM5 positive tumors.
• eVOLVE-Lung02 A Phase III: Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC)
• Neo-Coast 2: Een open-label, gerandomiseerde fase II-studie in meerdere centra naar neoadjuvante en adjuvante behandeling bij patiënten met reseceerbare niet-kleincellige longkanker in een vroeg stadium (II tot IIIB)
• ProCaLung: The Project on Cancer of the Lung.
• RE-ALEC: A multicenter non-interventional cohort study to evaluate the real-world clinical management and outcomes of patients diagnosed with ALK-positive advanced NSCLC treated with alectinib.
• TAK 788 3001: A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations.
  

Urologische oncologie

• CA2097DX trial: A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer.
• CORPORA: CheckpOint inhibition in advanced uRothelial carcinoma: PredictiOn of response through RNA profiling.
• DART trial: Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial.
• NIPITmelRCC: Predictie van immuuntherapie response en toxiciteit in melanoom en nierkanker door een transcriptoom gebaseerde immuun profilering.
• SGNDV-001/KN-D74: An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and greater).
• STORM-Peace - PEACE V: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases.
• TALAPRO-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer.
• Talapro-3 trial: A phase 3, randomized, double-blind study of Talazoparib with Enzalutamide versus placebo with enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer.

Orthopedie

Studieteam

• Dr. Hans Van der Bracht
• Dr. Luc Verhelst
• Dr. Verstuyft Lotte

Lopende studies

• Claviculafracturen 3D: Klinische, radiologische en 3D analyse van conservatief behandelde claviculafracturen.
• Schouder- en elleboogregister: Aanleggen van een database van de behandeling en follow-up van aandoeningen aan elleboog en schouder.
• Schouderprotheses na borst CA: Reverse schouderprothese bij patiënten met een voorgeschiedenis van borstcarcinoom: een retrospectieve cohort studie.
  claviculafracturen 3D Klinische, radiologische en 3D analyse van conservatief behandelde claviculafracturen.
• Subscapularis saving approach for reversed shoulder arthroplasty: a clinical and radiographical outcome study.

Spoedgevallen

Studieteam

• Dr. Kristof Buyse
• Dr. Philippe Leune

Lopende studies

• Spiking spoed: Kenmerken van spiking in Gent - een multicentrisch prospectief observationeel onderzoek.
• Aanmeldingstraject: Het aanmeldingstraject van patiënten op spoedgevallenzorg. Een prevalantiestudie binnen de niet-planbare zorg.